Pure Global
NCT06295029

Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and Genomics

Dose Optimization and Personalized Medication Software Research of BCL-2 Inhibitor Based on Machine Learning Combined With Genomics in Patients With Acute Myeloid Leukemia
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Myeloid Leukemia
Study type
Observational
Sponsor & location
Primary sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2024
End date
Dec 31, 2027
Enrollment
200 participants
Primary outcome

Overall survival (OS),Progression-free survival (PFS),Overall adverse event rate,Incidence of grade III and above adverse events

Summary

Severe neutropenia caused by venetoclax,a B-cell lymphoma-2(BCL-2) inhibitor, is the main
 cause of venetoclax tapering, drug discontinuation, and treatment delay. This study combines
 machine learning and genomics, hoping to develop models to predict venetoclax dose in Acute
 myeloid leukemia(AML) patients and compare the efficacy and safety differences of
 model-guided individualized medication regimen with current conventional regimen. According
 to the demographic information, the drug information, the drug concentration of the target
 patients, the laboratory examination, the single nucleotide polymorphism(SNP) information and
 the adverse reactions of the AML patients, and the model was constructed through machine
 learning.

ICD-10 classifications
Myeloid leukaemiaAcute myeloblastic leukaemia [AML]Myeloid leukaemia, unspecifiedAcute myelomonocytic leukaemiaAcute myeloid leukaemia with 11q23-abnormality
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06295029
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06295029 through Pure Global AI's free database. This phase not specified trial is sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School and is currently Not yet recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.